



# Louisiana

## Genetic Testing of CADASIL Syndrome

**Policy #** 00319

**Original Effective Date:** 10/19/2011

**Current Effective Date:** 08/09/2021

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

### When Services Are Eligible for Coverage

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider genetic testing for NOTCH3 variant to confirm the diagnosis of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) syndrome in a patient to be **eligible for coverage\*\*** under the following conditions:

- Clinical signs, symptoms, and imaging results are consistent with CADASIL, indicating that the pretest probability of CADASIL is at least in the moderate-to-high range (see the Policy Guidelines section); AND
- The diagnosis of CADASIL is inconclusive following alternative methods of testing, including magnetic resonance imaging.

Based on review of available data, the Company may consider genetic testing to confirm the diagnosis of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) syndrome for individuals who are asymptomatic with a family member with a diagnosis of CADASIL syndrome to be **eligible for coverage\*\*** under EITHER of the following conditions:

- Targeted genetic testing of the known NOTCH3 familial variant if there is a family member (first- and second-degree relative) with a known variant; OR
- Genetic testing of NOTCH3 if the family member's genetic status is unknown (see Policy Guidelines section).

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

### When Services Are Considered Investigational

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, the Company considers genetic testing for a NOTCH3 variant to confirm the diagnosis of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) syndrome in all other situations to be **investigational**.\*

### Policy Guidelines

Genetic testing for NOTCH3 comprises targeted sequencing of specific exons (eg, exon 4 only, exons 2-6), general sequencing of NOTCH3 exons (eg, exons 2-24 or all 33 exons), or targeted testing for known NOTCH3 pathogenic variants. Skin biopsy should be reserved for patients where NOTCH3 genetic testing is inconclusive (e.g. variants of uncertain significance).

The probability that cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is present in an individualized assessment depends on numerous factors such as family history, symptoms, imaging results, and other specialized testing such as skin biopsy.

Pescini et al (2012) attempted to identify clinical factors that increase the likelihood of a pathogenic variant being present. Table PG1 summarizes the pooled frequency of clinical and radiologic features, and the points assigned for each finding. The authors recommended that a total score of 14 be used to select patients for testing, because this score resulted in a high sensitivity (96.7%) and a moderately high specificity (74.2%).

**Table PG1. Pooled Frequency of Clinical and Radiologic Features**

Features	No. With <i>NOTCH3</i> Variant	Percent With <i>NOTCH3</i> Variant	Points
<i>Clinical</i>			
Migraine	239/463	52%	1
Migraine with aura	65/85	76%	3

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

Transient ischemic attack/stroke	380/526	72%	1 (2 if <50 y)
Psychiatric disturbance	106/380	28%	1
Cognitive decline	188/434	43%	3
<i>Radiologic</i>			
LE	277/277	100%	3
LE extended to temporal pole	174/235	74%	1
LE extended to external capsule	228/303	75%	5
Subcortical infarcts	210/254	83%	2

Adapted from Pescini et al (2012).

LE: leukoencephalopathy; No: number.

### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates in 2017 (see Table PG2). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organisation, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG3 shows the recommended standard terminology - “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”-to describe variants identified that cause Mendelian disorders.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

**Table PG2. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG3. ACMG-AMP Standards and Guidelines for Variant Classification**

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

### **Background/Overview**

#### **CADASIL**

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an uncommon, autosomal dominant disease, though it is the most common cause of hereditary stroke and hereditary vascular dementia in adults. CADASIL syndrome is an adult-onset, disabling systemic condition, characterized by a migraine with aura, recurrent lacunar strokes, progressive cognitive impairment, and psychiatric disorders. The overall prevalence of the disease is unknown in the general population.

#### **Diagnosis**

The differential diagnosis of CADASIL includes the following conditions (Table 1).

**Table 1. Differential Diagnosis of CADASIL**

<b>Acquired Disorders</b>	<b>Inherited Disorders</b>
<ul style="list-style-type: none"> <li>• Sporadic SVD with or without hypertension as the main risk factor</li> <li>• Multiple sclerosis</li> <li>• Primary angiitis of the central nervous system</li> </ul>	<ul style="list-style-type: none"> <li>• Fabry disease</li> <li>• Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy</li> <li>• Familial SVD caused by heterozygous variants in the <i>HTRA1</i> gene</li> <li>• Some forms of leukodystrophy</li> </ul>

CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; SVD: small vessel disease.

Since the clinical presentation of CADASIL varies, the condition may be confused with multiple sclerosis, Alzheimer dementia, and Binswanger disease. The specific clinical signs and symptoms, along with family history and brain magnetic resonance imaging findings, are extremely important in diagnosing CADASIL. The clinical features and mode of inheritance (autosomal dominant vs. autosomal recessive) help to distinguish CADASIL from other inherited disorders in a differential diagnosis.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

When the differential diagnosis includes CADASIL, various diagnostic tests are available:

- Genetic testing, by direct sequencing of select exons or of exons 2 through 24 of the *NOTCH3* gene (see the Rationale section). Identification of a *NOTCH3* pathogenic variant definitively establishes a diagnosis of CADASIL without the need for additional diagnostic testing (eg, skin biopsy).
- Immunohistochemistry assay of a skin biopsy sample, using a monoclonal antibody with reactivity against the extracellular domain of the *NOTCH3* receptor. Positive immunostaining reveals the accumulation of the NOTCH3 protein in the walls of small blood vessels. Lesnick Oberstein et al (2003) estimated the sensitivity and specificity at 85% to 90% and 95% to 100%, respectively, for 2 observers of the test results in a population of patients and controls correlated with clinical, genetic, and magnetic resonance imaging parameters.
- Detection of granular osmiophilic material in the same skin biopsy sample by electron microscopy. The major component of granular osmiophilic material is the ectodomain of the *NOTCH3* gene product. Granular osmiophilic material accumulates directly in vascular smooth muscle cells and, when present, is considered a hallmark of the disease. However, granular osmiophilic material may not be present in all biopsy samples. Sensitivity has been reported as low as 45% and 57% but specificity is generally near or at 100%.
- Examination of brain tissue for the presence of granular osmiophilic material was originally described as limited to brain blood vessels. Examination of brain biopsy or autopsy after death was an early criterion standard for diagnosis. In some cases, peripheral staining for granular osmiophilic material has been absent even though positive results were seen in brain blood vessels.

### ***NOTCH3* Variants**

Variants in *NOTCH3* have been identified as the underlying cause of CADASIL. In almost all cases, the pathogenic variants lead to loss or gain of a cysteine residue that can lead to increased reactivity of the NOTCH3 protein, resulting in ligand-binding and toxic effects.

The *NOTCH3* gene is found on chromosome 19p13.2-p13.1 and encodes the third discovered human homologue of the *Drosophila melanogaster* type I membrane protein NOTCH. The NOTCH3 protein consists of 2321 amino acids, primarily expressed in vascular smooth muscle cells, and plays an important role in the control of vascular transduction. It has an extracellular ligand-binding

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

domain of 34 epidermal growth factor (EGF)-like repeats, traverses the membrane once, and has an intracellular domain required for signal transduction.

Variants in the *NOTCH3* gene have been differentiated into those causative of the CADASIL syndrome (pathogenic variants) and those of uncertain significance. Pathogenic variants affect conserved cysteine residues within 34 EGF-like repeat domains in the extracellular portion of the NOTCH3 protein. More than 150 pathogenic variants have been reported in at least 500 pedigrees. *NOTCH3* has 33 exons but all CADASIL variants reported to date have occurred in exons 2 to 24, which encode the 34 EGF-like repeats, with strong clustering in exons 3 and 4, which encode EGF receptors 2 to 5 (>40% of variants in >70% of families occur in these exons). Some studies have indicated that the clinical variability in CADASIL presentation, particularly about the development of white-matter hyperintensities on magnetic resonance imaging, may be related to genetic modifiers outside the *NOTCH3* locus but the specific role of these modifiers is not well-delineated.

The probability that CADASIL is present in an individualized assessment depends on numerous factors such as family history, symptoms, imaging results, and other specialized testing (eg, skin biopsy). Pescini et al (2012) attempted to identify clinical factors that increase the likelihood of a pathogenic variant being present, with increasing likelihood with the presence of 1 or several factors, including a migraine, migraine with aura, transient ischemic attack/stroke, psychiatric disturbance, cognitive decline, leukoencephalopathy (with greater risk for leukoencephalopathy extending to the temporal pole or external capsule), and subcortical infarcts.

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Genetic testing of *NOTCH3* is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

### **Rationale/Source**

#### **Description**

Variants in the *NOTCH3* gene have been causally associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Genetic testing is available to determine if pathogenic variants exist in the *NOTCH3* gene for patients with suspected CADASIL and their family members.

#### **Summary of Evidence**

For individuals with suspected CADASIL syndrome who receive *NOTCH3* genetic testing, the evidence includes case reports, case series, and genotype-phenotype correlation studies evaluating the clinical validity and genetic testing yield for *NOTCH3*. Relevant outcomes are overall survival, test accuracy and validity, changes in reproductive decision making, change in disease status, and morbid events. The clinical validity studies have demonstrated that a *NOTCH3* pathogenic variant is found in a high percentage of patients with a clinical diagnosis of CADASIL, with studies reporting a clinical sensitivity of 90% to 100%. Limited data on specificity derives from testing small numbers of healthy controls, and no false-positive *NOTCH3* pathogenic variants have been reported in these populations. The diagnostic yield studies have reported a variable yield, ranging from 10% to 54%. These lower numbers likely reflect testing in heterogeneous populations that include patients with other disorders. No direct evidence was identified demonstrating outcome improvements associated with genetic testing for CADASIL. However, a chain of evidence can be constructed to demonstrate that identification of a *NOTCH3* pathogenic variant establishes the diagnosis of CADASIL without the need for a skin biopsy and reduces the need for other diagnostic tests used to exclude other conditions in a differential diagnosis. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic with family members who have CADASIL syndrome who receive targeted genetic testing for a known *NOTCH* familial variant, the evidence is limited. Relevant outcomes are overall survival, test accuracy and validity, changes in reproductive decision making, change in disease status, and morbid events. For asymptomatic family members of an individual with known CADASIL, knowledge of the presence of a familial variant may lead to changes in lifestyle decisions for the affected individual (eg, reproduction, employment). However, the impact of these lifestyle decisions on health outcomes is uncertain, and there are no interventions for asymptomatic individuals that are known to delay or prevent disease onset. A chain of evidence

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

can be constructed to demonstrate that identification of a *NOTCH3* familial variant predicts future development of CADASIL in an asymptomatic individual, eliminates the need for additional diagnostic testing, allows for earlier monitoring for development of systems, aids in reproductive planning, and helps determine the likelihood of an affected offspring. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic with family members who have CADASIL syndrome whose genetic status is unknown who receive *NOTCH3* genetic testing, the evidence is limited. Relevant outcomes are overall survival, test accuracy and validity, changes in reproductive decision making, change in disease status, and morbid events. For asymptomatic family members of an individual with known CADASIL whose genetic status is unknown, knowledge of the presence of a *NOTCH3* pathogenic variant may lead to changes in lifestyle decisions for the affected individual (eg, reproduction, employment). However, the impact of these lifestyle decisions on health outcomes is uncertain, and there are no interventions for asymptomatic individuals that are known to delay or prevent disease onset. A chain of evidence can be constructed to demonstrate that identification of a *NOTCH3* pathogenic variant predicts future development of CADASIL in an asymptomatic individual, eliminates the need for additional diagnostic testing, allows for earlier monitoring for development of systems, aids in reproductive planning, and helps determine the likelihood of an affected offspring. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### **Additional Information**

#### **2013 Input**

Given the high clinical sensitivity of genetic testing for CADASIL and the severity of the condition but no direct evidence on improvements in outcomes, clinical input was obtained in 2013. Input provided strong consensus that genetic testing for CADASIL syndrome is medically necessary when the diagnosis cannot be made by clinical presentation, magnetic resonance imaging, and skin biopsy results. In these cases, *NOTCH3* testing can confirm the diagnosis of CADASIL with a high degree of certainty. Input also provided strong consensus that testing is medically necessary for a first- or a second-degree relative when there is a known pathogenic variant in the family. In these cases, *NOTCH3* testing can predict the future development of CADASIL to permit earlier initiation of surveillance for symptoms and determine the likelihood of an affected offspring.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

## **Supplemental Information**

### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

#### **2013 Input**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 1 physician specialty society and 3 academic medical centers while this policy was under review in 2013. Most reviewers disagreed with the statement that genetic testing to confirm the diagnosis of CADASIL was investigational. All reviewers expressed support for testing to confirm the diagnosis in select patients, particularly when the diagnosis of CADASIL is inconclusive, and when the pretest likelihood of CADASIL is moderate to high. In addition to consensus among reviewers, contextual factors in support of medical necessity are present for this indication, ie, there is a highly suggestive chain of evidence; high-quality trials are unlikely to be performed, and there is a potential for reducing harms by avoiding additional testing and avoiding anticoagulants and antiplatelet agents when the disease is present.

Reviewers also agreed with the recommendation that testing is medically necessary for a first- or second-degree relative when there is a known pathogenic variant (familial variant) in the family. For this indication, contextual factors in support of medical necessity were not present. High-quality trials are unlikely to be performed.

#### **2020 Input**

Clinical consultation was obtained in 2020 indicating that skin biopsy prior to NOTCH3 testing is not necessary; skin biopsy should be reserved for patients where NOTCH3 genetic testing is inconclusive (e.g. variants of uncertain significance).

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

In 2010, the European Federation of Neurological Societies' guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias noted that most *NOTCH3* pathogenic variants occur within exons 3 and 4 and suggested direct sequencing of these 2 exons if clinical suspicion is high.

In 2020, a European Academy of Neurology Delphi consensus panel on important clinical questions related to management of monogenic cerebral small-vessel disease reports:

- CADASIL can only be definitively confirmed by genetic testing, revealing a *NOTCH3* mutation altering the number of cysteines in one of the 34 EGF<sub>R</sub> domains of the NOTCH3 protein
- CADASIL can be established by skin biopsy, but genetic testing should be the first diagnostic line investigation
- In the case of a *NOTCH3* variant of unknown significance, CADASIL can be confirmed using a skin biopsy for electron microscopy and/or *NOTCH3* immunostaining

### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

### Ongoing and Unpublished Clinical Trials

One currently ongoing trial that might influence this review is listed in Table 4.

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT04310098	Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Registry Study	1000	Mar 2049

### References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Genetic Testing of CADASIL Syndrome”, 2.04.75, May 2021.
2. Pescini F, Nannucci S, Bertaccini B, et al. The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. *Stroke*. Nov 2012; 43(11): 2871-6. PMID 22996955
3. Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. *Lancet*. Dec 15 2001; 358(9298): 2049-51. PMID 11755616
4. Lesnik Oberstein SA, van Duinen SG, van den Boom R, et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. *Acta Neuropathol*. Aug 2003; 106(2): 107-11. PMID 12756589
5. Muqtadar H, Testai FD. Single gene disorders associated with stroke: a review and update on treatment options. *Curr Treat Options Cardiovasc Med*. Jun 2012; 14(3): 288-97. PMID 22528196
6. del Rio-Espinola A, Mendioroz M, Domingues-Montanari S, et al. CADASIL management or what to do when there is little one can do. *Expert Rev Neurother*. Feb 2009; 9(2): 197-210. PMID 19210195
7. Malandrini A, Gaudio C, Gambelli S, et al. Diagnostic value of ultrastructural skin biopsy studies in CADASIL. *Neurology*. Apr 24 2007; 68(17): 1430-2. PMID 17452591
8. Brulin P, Godfraind C, Leteurtre E, et al. Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. *Acta Neuropathol*. Sep 2002; 104(3): 241-8. PMID 12172909
9. Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. *Neurology*. Oct 22 2002; 59(8): 1134-8. PMID 12395806

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

10. Choi JC, Lee KH, Song SK, et al. Screening for NOTCH3 gene mutations among 151 consecutive Korean patients with acute ischemic stroke. *J Stroke Cerebrovasc Dis.* Jul 2013; 22(5): 608-14. PMID 22133740
11. Mosca L, Marazzi R, Ciccone A, et al. NOTCH3 gene mutations in subjects clinically suspected of CADASIL. *J Neurol Sci.* Aug 15 2011; 307(1-2): 144-8. PMID 21616505
12. Rutten J, Lesnik Oberstein SAJ. CADASIL. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews.* Seattle, WA: University of Washington; 2016.
13. Donahue CP, Kosik KS. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. *Genomics.* Jan 2004; 83(1): 59-65. PMID 14667809
14. Chabriat H, Joutel A, Dichgans M, et al. Cadasil. *Lancet Neurol.* Jul 2009; 8(7): 643-53. PMID 19539236
15. Opherk C, Gonik M, Duering M, et al. Genome-wide genotyping demonstrates a polygenic risk score associated with white matter hyperintensity volume in CADASIL. *Stroke.* Apr 2014; 45(4): 968-72. PMID 24578207
16. Lee YC, Liu CS, Chang MH, et al. Population-specific spectrum of NOTCH3 mutations, MRI features and founder effect of CADASIL in Chinese. *J Neurol.* Feb 2009; 256(2): 249-55. PMID 19242647
17. Yin X, Wu D, Wan J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum in patients from mainland China. *Int J Neurosci.* 2015; 125(8): 585-92. PMID 25105908
18. Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. *Lancet.* Nov 22 1997; 350(9090): 1511-5. PMID 9388399
19. Abramycheva N, Stepanova M, Kalashnikova L, et al. New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). *J Neurol Sci.* Feb 15 2015; 349(1-2): 196-201. PMID 25623805
20. Maksemous N, Smith RA, Haupt LM, et al. Targeted next generation sequencing identifies novel NOTCH3 gene mutations in CADASIL diagnostics patients. *Hum Genomics.* Nov 24 2016; 10(1): 38. PMID 27881154
21. Peters N, Opherk C, Bergmann T, et al. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. *Arch Neurol.* Jul 2005; 62(7): 1091-4. PMID 16009764
22. Tikka S, Mykkanen K, Ruchoux MM, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. *Brain.* Apr 2009; 132(Pt 4): 933-9. PMID 19174371

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

23. Dotti MT, Federico A, Mazzei R, et al. The spectrum of Notch3 mutations in 28 Italian CADASIL families. *J Neurol Neurosurg Psychiatry*. May 2005; 76(5): 736-8. PMID 15834039
24. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. *Lancet Neurol*. Apr 2008; 7(4): 310-8. PMID 18296124
25. Huang L, Yang Q, Zhang L, et al. Acetazolamide improves cerebral hemodynamics in CADASIL. *J Neurol Sci*. May 15 2010; 292(1-2): 77-80. PMID 20227091
26. Peters N, Freilinger T, Opherck C, et al. Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. *J Neurol Sci*. Sep 15 2007; 260(1-2): 100-5. PMID 17531269
27. De Maria R, Campolo J, Frontali M, et al. Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: a randomized controlled trial. *Stroke*. Oct 2014; 45(10): 2959-66. PMID 25184356
28. Burgunder JM, Finsterer J, Szolnoki Z, et al. EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. *Eur J Neurol*. May 2010; 17(5): 641-8. PMID 20298421
29. Mancuso M, Arnold M, Bersano A, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. *Eur J Neurol*. Jun 2020; 27(6): 909-927. PMID 32196841

## **Policy History**

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

- |            |                                                                                                                                                          |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10/06/2011 | Medical Policy Committee review                                                                                                                          |
| 10/19/2011 | Medical Policy Implementation Committee approval. New policy.                                                                                            |
| 11/01/2012 | Medical Policy Committee review                                                                                                                          |
| 11/28/2012 | Medical Policy Implementation Committee approval. Coverage eligibility unchanged.                                                                        |
| 02/19/2013 | Coding updated                                                                                                                                           |
| 12/12/2013 | Medical Policy Committee review                                                                                                                          |
| 12/18/2013 | Medical Policy Implementation Committee approval. Coverage changed from investigational to eligible for coverage for certain indications. Title changed. |
| 12/04/2014 | Medical Policy Committee review                                                                                                                          |

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

- 12/17/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
- 12/03/2015 Medical Policy Committee review
- 12/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 12/01/2016 Medical Policy Committee review
- 12/21/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
- 12/07/2017 Medical Policy Committee review
- 12/20/2017 Medical Policy Implementation Committee approval. The policy is revised with updated genetics nomenclature. “Mutations” changed to “variants” in policy statements. Added “Notch 3” to all policy statements. Eligible for coverage statement added for testing in asymptomatic and pre-symptomatic family members of individuals with CADASIL. Investigational statement intent remains unchanged, altered for clarification. Policy Guidelines section added to the policy.
- 12/06/2018 Medical Policy Committee review
- 12/19/2018 Medical Policy Implementation Committee approval. Editorial change to coverage section to use “variant” terminology. Coverage eligibility unchanged.
- 12/05/2019 Medical Policy Committee review
- 12/11/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 07/02/2020 Medical Policy Committee review
- 07/08/2020 Medical Policy Implementation Committee approval. Removed skin biopsy from the first and second Patient Selection Criteria bullets for genetic testing for NOTCH3 variant to confirm the diagnosis of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) syndrome. For individuals who are asymptomatic with a family member diagnosed with CADASIL syndrome, added “(first- and second-degree relative)” to specify degree of family members to the first bullet of the Patient Selection Criteria.
- 07/01/2021 Medical Policy Committee review

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

07/14/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 07/2022

### **Coding**

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

*The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.*

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	81406
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

**\*Investigational** – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
  2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
  3. Reference to federal regulations.

**\*\*Medically Necessary** (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Genetic Testing of CADASIL Syndrome

Policy # 00319

Original Effective Date: 10/19/2011

Current Effective Date: 08/09/2021

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.